Zetagen Therapeutics

aid: zetagen-therapeutics
name: Zetagen Therapeutics
description: Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company founded in 2015 and based in Syracuse,
  New York, where it has operated from laboratory space in the Central New York Biotech Accelerator at SUNY Upstate Medical
  University since 2017. It develops locally administered small-molecule therapies for metastatic and primary cancers to bone
  and other organs, built on a proprietary "Zeta" platform derived from the company's discovery of a new molecular pathway
  acting through the Met5-enkephalin / opioid growth factor receptor signalling axis. Its oncology pipeline includes ZetaMet
  (Zeta-BC-003) for metastatic breast cancer to bone, which received FDA Breakthrough Device Designation in December 2021
  and Health Canada authorisation for a Phase 2a study in January 2022 and reported Phase 2a results at ASCO in June 2026;
  ZetaMet-P (Zeta-PC-004) for prostate cancer; ZetaMAST (Zeta-MBC-005) for metastatic breast cancer in liver; Zeta-BC-007;
  and ZetaOnc. Its osteologic programme is ZetaFuse, a synthetic osteoinductive bone graft studied in anterior cervical discectomy
  and fusion. The company reached 64 worldwide patents in 2024, has been funded by NCI and NIAMS grants, a $5.34M Series A,
  a $9.79M Series B and an oversubscribed Series B1 closed in November 2025, and its shares trade on secondary markets. Zetagen
  Therapeutics runs no developer program and publishes no product API, developer portal or API documentation. The only machine-readable
  surface reachable without credentials is the WordPress REST content API behind zetagen.com, catalogued here.
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: true
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - openapi
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: open
  trial: false
  try_now: false
  public: true
  label: Open access
  confidence: low
  source:
  - authentication
  - security
  generated: '2026-09-02'
  method: derived
image: https://zetagen.com/wp-content/uploads/2021/08/zetagen-logo.png
url: https://raw.githubusercontent.com/api-evangelist/zetagen-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biopharmaceutical
- Oncology
- Bone Health
- Orthopedics
- Clinical Trials
- Life Sciences
- Drug Development
- Medical Devices
- content-api
tags_raw:
- Company
- biopharmaceuticals
- oncology
- bone-health
- orthopedics
- clinical-trials
- life-sciences
- drug-development
- medical-devices
- content-api
apis:
- aid: zetagen-therapeutics:zetagen-com-website-wordpress-rest
  name: Zetagen Therapeutics Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the Zetagen Therapeutics website at zetagen.com: the route index
    of the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://zetagen.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://zetagen.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Overlay
  url: overlays/zetagen-therapeutics-content-overlay.yaml
- type: Website
  url: https://zetagen.com/
- type: About
  url: https://zetagen.com/our-company/
- type: Science
  url: https://zetagen.com/the-science/
- type: Oncology
  url: https://zetagen.com/oncology-sector/
- type: Research
  url: https://zetagen.com/research-overview/
- type: RegulatoryStatus
  url: https://zetagen.com/research-overview/regulatory-status/
- type: ClinicalTrials
  url: https://zetagen.com/research-overview/clinical-trials/
- type: ExpandedAccessPolicy
  url: https://zetagen.com/research-overview/expanded-access-policy/
- type: Publications
  url: https://zetagen.com/news/publications/
- type: News
  url: https://zetagen.com/news/
- type: PressReleases
  url: https://zetagen.com/news/press-releases/
- type: BlogRSS
  url: https://zetagen.com/feed/
- type: Contact
  url: https://zetagen.com/contact-us/
- type: PatientResources
  url: https://zetagen.com/walk-with-you/
- type: PrivacyPolicy
  url: https://zetagen.com/privacy-statement-us/
- type: CookiePolicy
  url: https://zetagen.com/cookie-policy-eu/
- type: Disclaimer
  url: https://zetagen.com/disclaimer/
- type: LinkedIn
  url: https://www.linkedin.com/company/zetagen-therapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/zetagen-therapeutics_stock/
- type: Authentication
  url: authentication/zetagen-therapeutics-authentication.yml
- type: Conventions
  url: conventions/zetagen-therapeutics-conventions.yml
- type: Conformance
  url: conformance/zetagen-therapeutics-conformance.yml
- type: ErrorCatalog
  url: errors/zetagen-therapeutics-problem-types.yml
- type: Lifecycle
  url: lifecycle/zetagen-therapeutics-lifecycle.yml
- type: DataModel
  url: data-model/zetagen-therapeutics-data-model.yml
- type: WellKnown
  url: well-known/zetagen-therapeutics-well-known.yml
- type: DomainSecurity
  url: security/zetagen-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/zetagen-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-05'
  status: enriched
  artifacts_added: 16
  pass: local-v1